TWI355935B - Combination of a taxane and a cyclin-dependent kin - Google Patents

Combination of a taxane and a cyclin-dependent kin Download PDF

Info

Publication number
TWI355935B
TWI355935B TW091105567A TW91105567A TWI355935B TW I355935 B TWI355935 B TW I355935B TW 091105567 A TW091105567 A TW 091105567A TW 91105567 A TW91105567 A TW 91105567A TW I355935 B TWI355935 B TW I355935B
Authority
TW
Taiwan
Prior art keywords
days
administered
patent application
docetaxel
floripone
Prior art date
Application number
TW091105567A
Other languages
English (en)
Chinese (zh)
Inventor
Bissery Marie-Christine
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Application granted granted Critical
Publication of TWI355935B publication Critical patent/TWI355935B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/453Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TW091105567A 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kin TWI355935B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27794801P 2001-03-23 2001-03-23
US30269201P 2001-07-05 2001-07-05
US33491601P 2001-12-04 2001-12-04

Publications (1)

Publication Number Publication Date
TWI355935B true TWI355935B (en) 2012-01-11

Family

ID=27402954

Family Applications (1)

Application Number Title Priority Date Filing Date
TW091105567A TWI355935B (en) 2001-03-23 2002-03-22 Combination of a taxane and a cyclin-dependent kin

Country Status (33)

Country Link
US (2) US20020182204A1 (https=)
EP (1) EP1372652B1 (https=)
JP (1) JP2004521140A (https=)
KR (1) KR100879712B1 (https=)
CN (1) CN1498107A (https=)
AR (1) AR034222A1 (https=)
AT (1) ATE395917T1 (https=)
AU (1) AU2002312815B2 (https=)
BR (1) BR0208221A (https=)
CA (1) CA2441441C (https=)
CY (1) CY1110449T1 (https=)
CZ (1) CZ301423B6 (https=)
DE (1) DE60226710D1 (https=)
DK (1) DK1372652T3 (https=)
EA (1) EA007815B1 (https=)
ES (1) ES2305253T3 (https=)
HR (1) HRPK20030766B3 (https=)
HU (1) HU229258B1 (https=)
IL (2) IL158058A0 (https=)
ME (1) MEP16408A (https=)
MX (1) MXPA03007743A (https=)
NO (1) NO332441B1 (https=)
NZ (1) NZ527655A (https=)
PE (1) PE20020907A1 (https=)
PL (1) PL206118B1 (https=)
PT (1) PT1372652E (https=)
RS (1) RS50681B (https=)
SI (1) SI1372652T1 (https=)
SK (1) SK287481B6 (https=)
TW (1) TWI355935B (https=)
UY (1) UY27220A1 (https=)
WO (1) WO2002076484A2 (https=)
ZA (1) ZA200307381B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361746T1 (de) * 2002-03-06 2007-06-15 Medical Res And Education Trus Botanischer extrakt mit antikrebs-aktivität enthaltend isoliquiritigenin
WO2004035034A2 (en) * 2002-10-16 2004-04-29 Ilex Products, Inc. Clofarabine and taxane chemotherapy combination
BR0316010A (pt) * 2002-11-06 2005-09-13 Cyclacel Ltd Combinação
US8084027B2 (en) * 2006-02-10 2011-12-27 Nerviano Medical Sciences S.R.L. Combinations comprising a CDK inhibitor and a growth factor antibody or anti-mitotic
CN104220066A (zh) * 2010-11-19 2014-12-17 皮拉马尔企业有限公司 紫杉醇和cdk抑制剂药物组合物
EP2694056B1 (en) 2011-04-01 2019-10-16 AstraZeneca AB Therapeutic treatment
PH12014500943A1 (en) 2011-11-30 2014-06-30 Astrazeneca Ab Combination treatment of cancer
AU2013204533B2 (en) 2012-04-17 2017-02-02 Astrazeneca Ab Crystalline forms

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) * 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
MX9102128A (es) * 1990-11-23 1992-07-08 Rhone Poulenc Rorer Sa Derivados de taxano,procedimiento para su preparacion y composicion farmaceutica que los contiene
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU2195297A (en) * 1996-02-20 1997-09-02 Sloan-Kettering Institute For Cancer Research Combinations of pkc inhibitors and therapeutic agents for treating cancers

Also Published As

Publication number Publication date
CY1110449T1 (el) 2015-04-29
CA2441441A1 (en) 2002-10-03
DE60226710D1 (de) 2008-07-03
HUP0303589A3 (en) 2007-05-02
US20060128640A1 (en) 2006-06-15
HRP20030766A2 (en) 2005-06-30
CZ301423B6 (cs) 2010-02-24
EP1372652B1 (en) 2008-05-21
HU229258B1 (en) 2013-10-28
SK287481B6 (sk) 2010-11-08
NO20034124L (no) 2003-09-16
RS50681B (sr) 2010-06-30
ZA200307381B (en) 2005-03-30
PT1372652E (pt) 2008-07-24
PL367702A1 (en) 2005-03-07
US20020182204A1 (en) 2002-12-05
PL206118B1 (pl) 2010-07-30
SI1372652T1 (sl) 2008-10-31
ES2305253T3 (es) 2008-11-01
PE20020907A1 (es) 2002-12-19
IL158058A0 (en) 2004-03-28
MXPA03007743A (es) 2004-11-12
EA007815B1 (ru) 2007-02-27
AU2002312815B2 (en) 2006-08-24
BR0208221A (pt) 2004-03-02
ATE395917T1 (de) 2008-06-15
CN1498107A (zh) 2004-05-19
NO332441B1 (no) 2012-09-17
IL158058A (en) 2010-02-17
MEP16408A (en) 2010-10-10
HRPK20030766B3 (en) 2006-11-30
HUP0303589A2 (hu) 2004-03-01
YU69503A (sh) 2006-08-17
UY27220A1 (es) 2002-09-30
AR034222A1 (es) 2004-02-04
CZ20032551A3 (en) 2004-07-14
NZ527655A (en) 2006-03-31
CA2441441C (en) 2009-05-26
EP1372652A2 (en) 2004-01-02
SK11692003A3 (sk) 2004-03-02
JP2004521140A (ja) 2004-07-15
WO2002076484A2 (en) 2002-10-03
KR100879712B1 (ko) 2009-01-22
WO2002076484A3 (en) 2003-01-03
DK1372652T3 (da) 2008-09-22
NO20034124D0 (no) 2003-09-16
KR20030086318A (ko) 2003-11-07
EA200301053A1 (ru) 2004-02-26

Similar Documents

Publication Publication Date Title
EP2127652B1 (en) Method for treating cancer using anticancer agent in combination
CN110934873B (zh) 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用
JP7660595B2 (ja) Cyp2c8及びcyp3a4の二重基質、糖質コルチコイド・レセプター・モジュレーターのリラコリラント及びパクリタキセルの併用投与
EP2387401A1 (en) Method for treating colorectal cancer
TWI355935B (en) Combination of a taxane and a cyclin-dependent kin
WO2020049139A1 (en) Urea derivatives for use in the treatment of subjects with elevated expression and/or activity of srpk1
US10213436B2 (en) Methods of treating cancer using aurora kinase inhibitors
ES3030540T3 (en) Treatment of breast cancer using combination therapies comprising gdc-9545 and gdc-0077
JP2018522936A (ja) ぶどう膜黒色腫の処置のためのmdm2阻害剤
JP7332589B2 (ja) 癌を治療するためのmdm2阻害剤とerkの阻害剤との組合せ
CN104415332A (zh) 异硫氰酸酯类化合物与激酶抑制剂类药物在癌症治疗中的联合应用
KR101847252B1 (ko) 이리노테칸염산염 수화물을 함유하는 항종양제
AU2002312815A1 (en) Combination of a taxane and a cyclin-dependent kinase inhibitor
WO2021048417A1 (en) Combination therapies comprising dasatinib for the treatment of cholangiocarcinoma
JP4429732B2 (ja) 癌の処置におけるグリベック(sti571)とサイクリン依存性キナーゼインヒビター、とりわけフラボピリドールとの組合せ剤
JP7536118B2 (ja) グルココルチコイド受容体モジュレーターレラコリラントおよびcyp2c8基質の併用投与
Bandivadekar et al. Cdk 4/6 inhibitors revolutionized breast cancer therapy
JP2024165887A (ja) Tcf3-hlf型b細胞性急性リンパ性白血病の治療剤
WO2021048418A1 (en) Combination therapies comprising bortezomib for the treatment of cholangiocarcinoma
CN101198253A (zh) 治疗癌症的组合、方法和组合物

Legal Events

Date Code Title Description
MM4A Annulment or lapse of patent due to non-payment of fees